SpliceBio has raised $135 million in Series B financing to advance its lead programme, SB-007, for Stargardt disease and to expand its pipeline of genetic medicines. The round was co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund and existing investors.

SB-007 is the first dual AAV gene therapy for Stargardt disease cleared by both the FDA and UK’s MHRA. It uses SpliceBio’s Protein Splicing platform to deliver large genes such as ABCA4, which are too large for conventional AAV vectors.